Business Description
Vericel Corp
NAICS : 541715
SIC : 2836
ISIN : US92346J1088
Total Employee Number:
398Compare
Compare
Traded in other countries / regions
VCEL.USAATQP.Germany Index Membership
Russell 2000Russell 3000 IPO Date
1997-02-04Description
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.76 | |||||
Equity-to-Asset | 0.74 | |||||
Debt-to-Equity | 0.25 | |||||
Debt-to-EBITDA | 2.91 | |||||
Interest Coverage | 28.49 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 9.7 | |||||
Beneish M-Score | -2.69 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 15 | |||||
3-Year FCF Growth Rate | 30.4 | |||||
3-Year Book Growth Rate | 19.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 60.89 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 17.97 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 24.42 | |||||
9-Day RSI | 29.93 | |||||
14-Day RSI | 35.54 | |||||
3-1 Month Momentum % | 36.42 | |||||
6-1 Month Momentum % | 30.91 | |||||
12-1 Month Momentum % | 30.15 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.04 | |||||
Quick Ratio | 4.69 | |||||
Cash Ratio | 3.09 | |||||
Days Inventory | 83.64 | |||||
Days Sales Outstanding | 85.19 | |||||
Days Payable | 78.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.3 | |||||
Shareholder Yield % | -0.18 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 74.56 | |||||
Operating Margin % | 5.95 | |||||
Net Margin % | 7.91 | |||||
EBITDA Margin % | 10.37 | |||||
FCF Margin % | 20.13 | |||||
OCF Margin % | 22.75 | |||||
ROE % | 7.08 | |||||
ROA % | 5.12 | |||||
ROIC % | 5.92 | |||||
3-Year ROIIC % | 13.84 | |||||
ROC (Joel Greenblatt) % | 10.87 | |||||
ROCE % | 6.04 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 87.15 | |||||
Forward PE Ratio | 74.59 | |||||
PE Ratio without NRI | 87.15 | |||||
Price-to-Owner-Earnings | 487.62 | |||||
PS Ratio | 7.14 | |||||
PB Ratio | 5.66 | |||||
Price-to-Tangible-Book | 5.74 | |||||
Price-to-Free-Cash-Flow | 35.07 | |||||
Price-to-Operating-Cash-Flow | 31.08 | |||||
EV-to-EBIT | 78.83 | |||||
EV-to-EBITDA | 63.86 | |||||
EV-to-Revenue | 6.62 | |||||
EV-to-Forward-Revenue | 6.06 | |||||
EV-to-FCF | 32.88 | |||||
Price-to-GF-Value | 0.76 | |||||
Price-to-Projected-FCF | 4.24 | |||||
Price-to-Median-PS-Value | 0.9 | |||||
Price-to-Graham-Number | 4.72 | |||||
| Price-to-Net-Current-Asset-Value | 15.88 | |||||
| Price-to-Net-Cash | 70.62 | |||||
Earnings Yield (Greenblatt) % | 1.27 | |||||
FCF Yield % | 2.94 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VCEL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vericel Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 306.303 | ||
| EPS (TTM) ($) | 0.47 | ||
| Beta | 0.9219 | ||
| 3-Year Sharpe Ratio | 0.29 | ||
| 3-Year Sortino Ratio | 0.49 | ||
| Volatility % | 45.05 | ||
| 14-Day RSI | 35.54 | ||
| 14-Day ATR ($) | 1.493509 | ||
| 20-Day SMA ($) | 43.784 | ||
| 12-1 Month Momentum % | 30.15 | ||
| 52-Week Range ($) | 28.95 - 49.32 | ||
| Shares Outstanding (Mil) | 51.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vericel Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vericel Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-26 08:30 | In 182 days | ||
| Annual report for 2026 | 2027-02-26 | In 181 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 181 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-06 08:30 | In 70 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 69 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-30 08:30 | 46.62 (+0.06%) | ||
| Second quarter earnings results for 2026 | 2026-07-30 | 46.62 (+0.06%) | ||
| Guidance call for 2026 | 2026-06-16 11:20 | 38.29 (+2.19%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:30 | 36.78 (-2.15%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 36.78 (-2.15%) |
Show
Entries
Vericel Corp Frequently Asked Questions
What is Vericel Corp(VCEL)'s stock price today?
The current price of VCEL is $40.96. The 52 week high of VCEL is $49.32 and 52 week low is $28.95.
When is next earnings date of Vericel Corp(VCEL)?
The next earnings date of Vericel Corp(VCEL) is 2026-11-06 Est..
Does Vericel Corp(VCEL) pay dividends? If so, how much?
Vericel Corp(VCEL) does not pay dividend.
Guru Commentaries on NAS:VCEL
Conestoga Micro Cap Composite
Bullish
2026 Q2
What the manager wrote
Vericel Corp. (VCEL) was a standout performer in our portfolio, significantly contributing to our returns during the quarter. We have identified VCEL as a high-quality growth business that meets our investment standards while providing exposure to unique growth opportunities in the biotechnology sector. Despite the challenges in the broader market, we remain confident in Vericel's potential for durable earnings growth, which aligns with our focus on high-quality growth businesses with competitive advantages.
Ncg Micro Cap Growth Strategy
Bullish
2026 Q1
What the manager wrote
We added Vericel to our portfolio in Q1 due to its strong business fundamentals and growth potential. The company operates in the health care sector, which we believe has significant opportunities for high-quality growth. Our investment philosophy focuses on identifying companies with sustainable competitive advantages, and we see Vericel as a strong candidate in this regard. The health care sector is currently underweight in our portfolio, but we are selectively investing in companies like Vericel that we believe can sustain high growth.
Press Release
Articles on Vericel Corp
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers